Sofia Aakko
YOU?
Author Swipe
View article: Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study
Transfusion independence, hematological improvement and associated safety outcomes with bexmarilimab and azacitidine in HR-MDS: Results of the bexmab Phase 1/2 study Open
Introduction Hypomethylating (HMA) agents, including azacitidine, are standard frontline agents for HR MDS patients with complete remission (CR) rates approximately 16% (Hasegawa et al., 2023). In those with primary refractory or relapsed …
View article: Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study
Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study Open
Introduction Bexmarilimab is a novel macrophage checkpoint inhibitor targeting Clever-1, a scavenger receptor expressed on malignant blasts and monocytes in myelodysplastic syndromes (MDS) bone marrow (BM). Tumor protein 53 (TP53) is mutat…
View article: Predictors of response and rational combinations for the novel <scp>MCL</scp> ‐1 inhibitor <scp>MIK665</scp> in acute myeloid leukemia
Predictors of response and rational combinations for the novel <span>MCL</span> ‐1 inhibitor <span>MIK665</span> in acute myeloid leukemia Open
Despite promising anti‐leukemic activity of MCL‐1 inhibitors in preclinical studies of acute myeloid leukemia (AML), clinical progress has been hindered by limited knowledge of target patient subgroups. To stratify patients for MCL‐1 inhib…
View article: Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia Open
Despite promising anti-leukemic activity of MCL-1 inhibitors in preclinical studies of acute myeloid leukemia (AML), their progress through clinical evaluation has in part been challenged by limited knowledge of patient subgroups suitable …
View article: Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia
Predictors of Response and Rational Combinations for the Novel MCL-1 Inhibitor MIK665 in Acute Myeloid Leukemia Open
Background Elevated MCL-1 expression has been shown to play a central role in apoptosis escape and to mediate primary resistance to the approved BCL-2 inhibitor venetoclax in acute myeloid leukemia (AML) (Li, 2019). Preclinical investigati…
View article: Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study
Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study Open
Introduction Treatment of myelodysplastic syndrome (MDS) with primary refractory disease or relapse after frontline treatment (r/r MDS) represents a high unmet medical need. Hypomethylating (HMA) agents, including azacitidine, are used in …
View article: P542: A PHASE I/II STUDY TO ASSESS SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF BEXMARILIMAB IN COMBINATION WITH STANDARD OF CARE IN PATIENTS WITH MYELOID MALIGNANCIES (BEXMAB)
P542: A PHASE I/II STUDY TO ASSESS SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF BEXMARILIMAB IN COMBINATION WITH STANDARD OF CARE IN PATIENTS WITH MYELOID MALIGNANCIES (BEXMAB) Open
Background: Clever-1 constitutes a novel macrophage checkpoint. Its expression in AML BM cells is a prognostic factor for poor outcome and its suppression inhibits leukemia cell growth (1). Analyses suggests lower expression is associated …
View article: Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia Open
Myeloid neoplasms with erythroid or megakaryocytic differentiation include pure erythroid leukemia, myelodysplastic syndrome with erythroid features, and acute megakaryoblastic leukemia (FAB M7) and are characterized by poor prognosis and …
View article: P380: EX VIVO IMMUNE ACTIVATION WITH THE MACROPHAGE-TARGETING IMMUNOTHERAPY, ANTI-CLEVER-1 ANTIBODY BEXMARILIMAB, IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
P380: EX VIVO IMMUNE ACTIVATION WITH THE MACROPHAGE-TARGETING IMMUNOTHERAPY, ANTI-CLEVER-1 ANTIBODY BEXMARILIMAB, IN ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME Open
Background: Despite the recent approvals of targeted therapeutic agents for acute myeloid leukemia (AML), the treatment options remain few and for myelodysplastic syndrome (MDS), even fewer. The potential of immunotherapies in these myeloi…